Print

Purpose

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.

Condition

Eligibility

Eligible Ages
Between 55 Years and 80 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Have a phosphorylated tau (P-tau) result consistent with the presence of amyloid pathology. - Have a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities. - Have adequate literacy, vision, and hearing for neuropsychological testing at screening. - Have a Mini Mental Status Exam (MMSE) score consistent with no to minimal cognitive impairment. - Have a Functional Activities Questionnaire (FAQ) score consistent with no to minimal functional impairment. - If currently receiving medications as symptomatic treatment for AD, dose has been stable for at least 30 days before screening.

Exclusion Criteria

  • Have dementia or significant other neurological disease that can affect cognition. - Have current serious or unstable illnesses that in the investigator's opinion, could interfere with the analyses of the study. - Have a history of cancer that, in the investigator's opinion, has a high risk of recurrence. - Have a history of clinically significant multiple or severe drug allergies, or hypersensitivity reactions. - Have a clinically important laboratory test result or other abnormality as determined by investigator that could be detrimental to the participant or could compromise the study. - Have any contraindications for magnetic resonance imaging (MRI). - Have a centrally read MRI demonstrating presence of ARIA-E, >4 cerebral microhemorrhages, any superficial siderosis, any macrohemorrhage, or severe white matter disease at screening. Prior or Current Therapies - Have had prior treatment with a passive anti-amyloid immunotherapy within <5 half-lives prior to screening. - Have received active immunization against Aβ in any other study.

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Double (Participant, Investigator)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Remternetug 		Remternetug administered subcutaneously (SC).
  • Drug: Remternetug
    Administered SC
    Other names:
    • LY3372993
Placebo Comparator
Placebo 		Placebo administered SC.
  • Drug: Placebo
    Administered SC

Recruiting Locations

The University of Texas Health Science Center at Houston
Houston, Texas 77054
Contact:
713-486-0536

More Details

Status
Recruiting
Sponsor
Eli Lilly and Company

Study Contact

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
3176154559
ClinicalTrials.gov@lilly.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.